Myung In Pharmaceutical LTD. (KRX:317450)

South Korea flag South Korea · Delayed Price · Currency is KRW
56,200
-500 (-0.88%)
At close: Apr 28, 2026
Market Cap 820.52B
Revenue (ttm) 287.25B
Net Income (ttm) 81.44B
Shares Out 14.60M
EPS (ttm) 6,718.00
PE Ratio 8.37
Forward PE n/a
Dividend 1,500.00 (2.61%)
Ex-Dividend Date Dec 29, 2025
Volume 22,217
Average Volume 23,378
Open 56,700
Previous Close 56,700
Day's Range 56,100 - 56,900
52-Week Range 52,000 - 134,500
Beta n/a
RSI 46.15
Earnings Date Apr 14, 2026

About KRX:317450

Myung In Pharmaceutical LTD., a pharmaceutical company, manufactures ETC and OTC drugs. It offers products in the areas of thrombosis and anti-platelet, anti-hypertensive, anti-angina, anti-parkinson, anti-dementia, anti-epileptics, anti-schizophrenia, anti-depressants, adhd, anti-insomnia, gum disease treatment, gastrointestinal, cold-cough medicine, anti-fever, anti-pain, anti-inflammation agent, nutrition supplements and other pharmaceuticals. The company also provides APIs, such as benztropine mesylate, benidipine hcl, clopidogrel bisulfate... [Read more]

Industry Pharmaceutical Preparations
Founded 1985
Employees 335
Stock Exchange Korea Stock Exchange
Ticker Symbol 317450
Full Company Profile

Financial Performance

In 2025, KRX:317450's revenue was 287.25 billion, an increase of 6.61% compared to the previous year's 269.43 billion. Earnings were 81.44 billion, an increase of 18.59%.

Financial Statements

News

There is no news available yet.